Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT · NASDAQ Capital Market
+$0.46 today
Vol 0.89M · Avg 0.12M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $3.3M |
| Other Current | $157.1K |
| Total Current Assets | $3.4M |
| PP&E (Net) | $850.1K |
| Other Non-current | $6.6M |
| Total Non-current Assets | $7.5M |
| Total Assets | $10.9M |
Analysis
Selected assets total $10.9M for Latest. The largest visible component is Other Non-current at $6.6M, about 60.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1M +391.5% | $1.0M -75.3% | $4.2M -21.5% | $5.4M +11.0% | $4.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 +100.0% | -$106.6K | $0 | $0 -100.0% | $150.2K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $5.2M +398.4% | $1.0M -75.9% | $4.3M -22.5% | $5.6M +9.2% | $5.1M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $7.6M | $0 | $0 | $0 | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 -100.0% | $106.6K | $0 | $0 | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $7.6M +6990.7% | $106.6K | $0 | $0 | $0 | -$15.3B | $14.8B | $11.3B |
| Total Assets | $12.7M +1011.6% | $1.1M -73.4% | $4.3M -22.5% | $5.6M +9.2% | $5.1M | $13.3B | $11.9B | $10.6B |
| Account Payables | $436.5M +524480.0% | $83.2K -31.0% | $120.5K -34.4% | $183.8K -5.0% | $193.5K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $69.1K | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $232.1K -1.3% | $235.1K +49.6% | $157.1K -4.8% | $165.0K | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | -$436.0M | $0 | $0 | $0 -100.0% | $77.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.3M +318.8% | $318.3K +1.4% | $313.9K -20.7% | $395.8K +30.6% | $302.9K | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $439.0K | $0 | $0 | $0 +100.0% | -$0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $439.0K | $0 | $0 | $0 +100.0% | -$0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $1.8M +456.8% | $318.3K +1.4% | $313.9K -20.7% | $395.8K +30.6% | $302.9K | $14.7B | $3.7B | $9.6B |
| Common Stock | $879 +290.7% | $225 +0.0% | $225 +35.5% | $166 -87.9% | $1.4K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$58.1M -11.5% | -$52.1M -7.4% | -$48.5M -11.7% | -$43.4M -17.0% | -$37.1M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $1.3M | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $11.0M +1225.1% | $827.2K -79.3% | $4.0M -22.7% | $5.2M +7.8% | $4.8M | $9.1B | $7.7B | $3.3B |
| Total Debt | $664.5K | $0 | $0 | $0 | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$4.4M -327.6% | -$1.0M +75.3% | -$4.2M +21.5% | -$5.4M -11.0% | -$4.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cingulate Inc.
CING
$28.65M
Allarity Therapeutics, Inc.
ALLR
$23.07M
Entero Therapeutics, Inc.
ENTO
$13.58M
Rocket One Inc.
HOTH
$13.52M
Lexaria Bioscience Corp.
LEXX
$12.27M
Kairos Pharma, Ltd.
KAPA
$9.69M
BriaCell Therapeutics Corp.
BCTX
$5.46M
Pulmatrix, Inc.
PULM
$5.30M
CASI Pharmaceuticals, Inc.
CASI
$2.33M
Clearside Biomedical, Inc.
CLSD
$2.15M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does LIXT have?
Lixte Biotechnology Holdings, Inc. (LIXT) reported $5.11M in cash and equivalents in fiscal 2025.
How much debt does LIXT carry?
Lixte Biotechnology Holdings, Inc. (LIXT) reported $664,491.00 of total debt, with net debt of -$4,442,381.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.